Search Within

Jonathan Eric Rosenberg

Formats
  1. Meeting Abstract (283)
  2. Journal Article (195)
  3. Review (18)
  4. Correspondence (10)
  5. Editorial (5)
  6. Guidelines (4)
  7. Book Section (2)
  8. Research Letter (2)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (520)
  2. Genitourinary Oncology Service (520)
  3. Solid Tumor Oncology Division (520)
  4. Department of Pathology and Laboratory Medicine (149)
  5. Surgery (140)
  6. Urology (137)

More Groups

People
  1. Dean Bajorin (204)
  2. Gopakumar Iyer (175)
  3. Hikmat Al-Ahmadie (134)
  4. Bernard Bochner (124)
  5. David Solit (114)
  6. Min Yuen Teo (75)

More People

Years
  1. 2025 (23)
  2. 2024 (36)
  3. 2023 (32)
  4. 2022 (36)
  5. 2021 (48)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (204)
  2. Annals of Oncology (42)
  3. European Urology (20)
  4. Clinical Genitourinary Cancer (18)
  5. Clinical Cancer Research (16)
  6. Cancer Research (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (210)
  2. Oxford University Press (47)
  3. Elsevier Inc. (39)
  4. Elsevier Science, Inc. (36)
  5. Nature Publishing Group (36)
  6. American Association for Cancer Research (35)

More Publishers

Results (520)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma
    Meeting Abstract

    Pond, G. R.; Sonpavde, G.; Galsky, M. D.; Sharma, P.; Rosenberg, J. E.; Choueiri, T. K.; Bellmunt, J.; Lee, J. L.; Lee, S. I.; Azrilevich, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab
    Meeting Abstract

    Pond, G. R.; Niegisch, G.; Rosenberg, J. E.; Dreicer, R.; Powles, T.; Necchi, A.; Wei, X. X.; Grivas, P.; Balar, A. V.; Galsky, M. D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • EV-201 study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy
    Meeting Abstract

    Rosenberg, J. E.; Heath, E. I.; O'Donnell, P. H.; Hahn, N. M.; Balar, A. V.; Gartner, E. M.; Melhem-Bertrandt, A.; Petrylak, D. P.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study
    Meeting Abstract

    Necchi, A.; Pond, G. R.; Plimack, E. R.; Niegisch, G.; Yu, E. Y.; Pal, S. K.; Bamias, A.; Agarwal, N.; Alva, A. S.; Srinivas, S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma
    Meeting Abstract

    Necchi, A.; Mariani, L.; Lo Vullo, S.; Raggi, D.; Giannatempo, P.; Bamias, A.; Crabb, S. J.; Bellmunt, J.; Yu, E. Y.; Niegisch, G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • EV-103 study: A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer
    Meeting Abstract

    Hoimes, C. J.; Petrylak, D. P.; Flaig, T. W.; Carret, A. S.; Melhem-Bertrandt, A.; Rosenberg, J. E.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Next generation sequencing of urothelial bladder cancer: Memorial Sloan Kettering Cancer Center experience in 454 patients
    Meeting Abstract

    Isharwal, S.; Audenet, F.; Drill, E. N.; Ostrovnaya, I.; Pietzak, E. J.; Al-Ahmadie, H.; Cha, E. K.; Donahue, T. F.; Teo, M. Y.; Funt, S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Defining the DNA damage repair (DDR) genomic landscape of urothelial carcinoma of the bladder (UCB)
    Meeting Abstract

    Dason, S.; McPherson, V.; Teo, M. Y.; Isharwal, S.; Audenet, F.; Bagrodia, A.; Cha, E. K.; Berger, M. F.; Zehir, A.; Schultz, N.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A tumor growth rate/overall survival model for atezolizumab as an early predictor of OS in patients with first or second line metastatic urothelial carcinoma
    Meeting Abstract

    Bruno, R.; Claret, L.; Wu, B.; Jin, J. Y.; Winter, H.; Cui, N.; Derleth, C. L.; Shen, X.; Girish, S.; Rosenberg, J. E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase I trial of dose-escalated image-guided, intensity modulated radiation therapy in combination with concurrent gemcitabine chemotherapy for node-negative, muscle-invasive bladder cancer (MIBC)
    Meeting Abstract

    Kollmeier, M. A.; Zelefsky, M. J.; McBride, S.; Debonis, D.; Lochansingh, S.; Varghese, M.; Bochner, B.; Rosenberg, J.; Bajorin, D.
    International Journal of Radiation Oncology, Biology, Physics (2018)

    Fulltext@MSK | Save